Jewellery in jeopardy

Acquires SaaS company for USD 120m

Norway: Best ideas Q2'25

Expert speaker call: latent market share gains

The Pandora Jewellery Box - May 2025

Telenor ASA: 1 director

A director at Telenor ASA bought 3,247 shares at 154.000NOK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Silicon Labs next gen chips: Too little, too late

SLAB Q2 guidance implies upside to Q2

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

True EBITDA flat q-o-q, but above ABGSC

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

Telenor (Sell, TP: NOK142.00) - Mixed set of results

While Telenor reported decent Q1 headline results adjusted for a one-off VAT provision in Norway, slightly above consensus and our estimates, the FCF beat was seemingly driven by lower-quality transitory tailwinds, leaving us still uncertain about its ability to cover its dividends with underlying FCF before M&A this year and in 2026. Thus, given our view of a stretched company and sector valuation, we reiterate our SELL, while we have raised our target price to NOK142 (140).

Stretched valuation and likely slowdown ahead

Growth unfolds, brand upholds

Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead

Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.

Shine on, for now

Telenor (Buy, TP: NOK 183, +17%) Q1 25: Strong results support contin...

Telenor has reported a good set of Q1 numbers, with SR c0.5% ahead of consensus and EBITDA in line; 2025 guidance was re-iterated, which is now in line with consensus expectations, but we think this could be raised later in the year if the further OpEx efficiencies management are expecting are realised.

Coffee, Croissants & Credit/Telenor, Heimstaden Bostad, Castellum

Telecom - Telenor reports good 1Q25 results

Nordics above, but other segments below